tiprankstipranks
The Fly

Acadia Pharmaceuticals initiates ACP-204 study

Acadia Pharmaceuticals initiates ACP-204 study

Acadia Pharmaceuticals announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ACAD:

Questions or Comments about the article? Write to editor@tipranks.com